Deep Functional Phenotyping of the ALA Lung Health Cohort

Description

The goal of this observational study is to learn about lung structure and function in a group of 1000 healthy people aged 25 to 35. The main questions it aims to answer are whether people's bodies, environment, and general lung health are associated with: * the structure of the participants lungs' airways, * the structure of blood vessels in the participants lungs and heart, and * the participants lungs' ability to exchange gases. Participants will take four different lung function tests to measure lung function, including: * air movement in the lungs (oscillometry) * lung size (slow vital capacity (SVC) and functional residual capacity (FRC) * gas transfer in the lungs (diffusing capacity for carbon monoxide (DLCO).

Conditions

Lung Diseases

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this observational study is to learn about lung structure and function in a group of 1000 healthy people aged 25 to 35. The main questions it aims to answer are whether people's bodies, environment, and general lung health are associated with: * the structure of the participants lungs' airways, * the structure of blood vessels in the participants lungs and heart, and * the participants lungs' ability to exchange gases. Participants will take four different lung function tests to measure lung function, including: * air movement in the lungs (oscillometry) * lung size (slow vital capacity (SVC) and functional residual capacity (FRC) * gas transfer in the lungs (diffusing capacity for carbon monoxide (DLCO).

The American Lung Association (ALA) Deep Phenotyping Ancillary Study of the Lung Health Cohort (LHC)

Deep Functional Phenotyping of the ALA Lung Health Cohort

Condition
Lung Diseases
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama, Birmingham, Alabama, United States, 35294

Los Angeles

University of California, Los Angeles, Los Angeles, California, United States, 90095

Denver

National Jewish Health, Denver, Colorado, United States, 80206

Jacksonville

Nemours Children's Jacksonville, Jacksonville, Florida, United States, 32207

Chicago

Northwestern University, Chicago, Illinois, United States, 60611

Kansas City

University of Kansas, Kansas City, Kansas, United States, 66103

Baltimore

Johns Hopkins University, Baltimore, Maryland, United States, 21218

Ann Arbor

University of Michigan, Ann Arbor, Michigan, United States, 48109

Durham

Duke University, Durham, North Carolina, United States, 27710

Winston-Salem

Wake Forest School of Medicine, Winston-Salem, North Carolina, United States, 27104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 25-35 years at the time of the baseline examination
  • * Able to read and understand English or Spanish
  • * Has a social security number
  • * Resident (citizen or non-citizen) of the United States (US) for at least 12 months prior to examination.
  • * Willing to provide contact information for at least 2 proxies who are likely to know the whereabouts and vital status of the participant
  • 1. Severe asthma, which is defined as any of the following:
  • * Current (i.e. at the time of the visit) Global Initiative for Asthma (GINA) Step 4 or higher therapy (medium dose inhaled corticosteroid/long-acting beta agonist (ICS/LABA) or high dose inhaled corticosteroid \[ICS\] or add-on long-acting muscarinic antagonist (LAMA); Medium dose = \>250 fluticasone, propionate =100 fluticasone furoate, \>200 beclomethasone, \>400 budesonide, \>220 mometasone). The investigators will accept low-dose ICS/LABA or medium dose ICS.
  • * 3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months OR
  • * One asthma hospitalization in the past 12 months
  • 2. History of any chronic lung disease other than asthma including but not limited to chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis, pulmonary hypertension
  • 3. Current pregnancy
  • 4. History of cancer other than non-melanoma skin cancer
  • 5. Diagnosed cardiovascular diseases (i.e., congenital heart disease, coronary heart disease)
  • 6. Inability to comply with study procedures, including
  • * Inability or unwillingness to provide informed consent
  • * Inability to perform study measurements
  • * Inability to be contacted by phone (via calls and/or text messaging) or email
  • 7. Any condition in the opinion of the physician that puts the participant at risk by participating in the study (e.g., serious respiratory illness requiring antibiotics or steroids or severe fever at the time of the study visit).
  • 8. Institutionalization

Ages Eligible for Study

25 Years to 35 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Johns Hopkins University,

Meredith McCormack, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

2026-07